Given zanubrutinib’s kinase-specific inhibition and manageable safety profile, it represents a promising targeted therapy for MYD88-mutated DLBCL, warranting further investigation in larger, prospective trials to confirm its efficacy and establish its role in this challenging patient population. Here, MYD88 is linked to diffuse large B-cell lymphoma.